

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

**VOLUNTARY ANNOUNCEMENT
CONSIGNED TECHNOLOGY DEVELOPMENT AGREEMENT
WITH
HARBIN GLORIA PHARMACEUTICALS CO., LTD.***

This is a voluntary announcement made by the Company.

THE CONSIGNED TECHNOLOGY DEVELOPMENT AGREEMENT

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 29 December 2017, its indirect wholly-owned subsidiary, Nanjing Jinsirui Biotechnology Co., Ltd.* (南京金斯瑞生物科技股份有限公司) (“**Genscript China**”) and Harbin Gloria Pharmaceuticals Co., Ltd.* (哈爾濱譽衡藥業股份有限公司) (“**Harbin Gloria**”) entered into a consigned technology development agreement, pursuant to which Genscript China agreed to undertake preclinical research and development of a biosimilar to Ipilimumab (trade name: Yervoy), a targeted immunotherapy for cancer, for Harbin Gloria.

Ipilimumab is a fully human monoclonal antibody, which specifically recognizes cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and blocks the inhibitory signal. CTLA-4 is a surface receptor in T cells and is upregulated after T cell activation. CTLA-4 is overexpressed in many cancer patients leading to abnormal growth of tumor cells. Blocking CTLA-4 enhances T cell activation and proliferation, which increases host immune responses.

INFORMATION ON HARBIN GLORIA

Harbin Gloria is incorporated in the People's Republic of China and is listed on The Shenzhen Stock Exchange with stock code 002437. Harbin Gloria is a China-based company, principally engaged in the manufacture and distribution of pharmaceuticals. Harbin Gloria is also engaged in the agency, research and development of pharmaceuticals including oncology medicines, and the provision of clinical services.

To the best of the knowledge, information and belief of the Directors, having made all reasonable enquiries, Harbin Gloria is a third party independent of the Company and its connected persons as at the date of this announcement.

INFORMATION ON THE GROUP AND GENSCRIPT CHINA

The Company and its subsidiaries (the “**Group**”) are principally engaged in the provision of (i) life sciences research services, (ii) life sciences research catalog products, (iii) preclinical drug development services, (iv) industrial synthetic biology products and (v) CAR-T cell immunotherapy.

Genscript China is a limited liability company incorporated in the People's Republic of China and is an indirect wholly-owned subsidiary of the Company.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 3 January 2018

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Huang Zuie-Chin and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

* *For identification purposes only*